Truace
Subscribe

Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI

Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational...

By the Truvace desk1 min read1 sourceJournalismTRV-2026-1229· cite & verify
Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI

In brief

Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement.

The partnership illustrates use of AI-driven protein design in pharmaceutical development, but the supplied text does not detail specific targets, timelines, performance results, or clinical outcomes, leaving efficacy and translational impact uncertain.

Main points

  1. Profluent announced a collaboration with BioMarin Pharmaceutical Inc.
  2. The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline.
  3. Under the agreement Profluent will apply its foundational AI technology to the effort.

The gain

Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.

The rundown

On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies.

The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline.

Sources

  1. JournalismMarketScreener2026-09-30

The debate